Thabor Therapeutics appoints Jérémie Mariau as CEO

Arrival of Jérémie Mariau will bolster company management team dedicated to finding new treatment options for patients affected by chronic mucosal inflammatory diseases, while it prepares for new funding round

Paris, France, May 17, 2022 – Thabor Therapeutics, a company developing an innovative treatment for patients living with chronic mucosal inflammatory diseases, today announces the appointment of Jérémie Mariau as CEO.

Mariau’s arrival as the head of Thabor Therapeutics will further bolster the senior management team. Thabor will then be able to launch a new funding round by the end of the year. The funds raised will allow the company to progress to the next key stages in its development, up to initiation of the first-in-human clinical trials.

“I am honored to join Thabor in this new entrepreneurial venture, working side-by-side with an incredibly experienced and complementary team,” said Jérémie Mariau. “The company’s novel first-in-class approach, aimed at re-instating epithelial homeostasis in the intestine, is a world first, and, as such, stands out from other approaches currently under development. It should provide patients with an effective long-term solution without the increased risk of infection and cancer associated with the use of existing treatments. I would like to thank Marina Guillet, co-founder of the company, who has worked hard on structuring the company since it was founded a year ago.”

The approach pursued by Thabor Therapeutics is based on more than ten years of research conducted by Eric Chevet, PhD, director of research at the Inserm 1242 unit in Rennes, and Eric Ogier-Denis, PhD, director of research into `Cellular Stress and Inflammatory Bowel Disease’ at Inserm, in close collaboration with Professor Xavier Treton, MD, PhD, a gastroenterologist at AP-HP (Assistance Publique – Hôpitaux de Paris university hospital center). Their work helped identify a new target maintaining endoplasmic reticulum homeostasis in healthy individuals; said target becoming secreted and deleterious in pathological conditions exerting pro-inflammatory and pro-fibrotic effects. Inhibiting this target may constitute a transformative approach for treating inflammatory bowel diseases and other mucosal inflammatory diseases. In industrialized countries, inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis affect more than seven million people, with over half of cases occurring in Europe.

“A treatment that helps to counteract the epithelial dysfunction that lies at the root of the mucosal inflammation occurring in patients living with chronic inflammatory bowel disease would plug a significant gap in treatment. To make it a reality, alongside a solid team of scientists, Thabor needs a strong management team to guide the development process. With his extensive knowledge of auto-immune and inflammatory diseases, Jérémie is the ideal man for the job,” said Professor Xavier Treton MD, PhD, gastroenterologist at AP-HP, and co-founder of Thabor Therapeutics.

“We are delighted to see Jérémie take the reins at Thabor Therapeutics. We also welcome him as an operating partner in our venture capital company,” said Alain Huriez, co-founder and president of AdBio partners. “We have total confidence in his ability to lead Thabor towards the next stages in its development thanks to his experience, his network and his personality. As a seed investor in Thabor Therapeutics, we fully believe in his potential. Jérémie’s arrival ensures the company has all the assets it needs to achieve its next objectives.”

With over 15 years’ experience working with biotech companies, Jérémie Mariau has held several high-ranking positions and set up a number of industrial partnerships, most notably with Servier. From 2013 to 2020, he was CEO of ILTOO Pharma, a clinical-stage biotech company specializing in auto-immune and inflammatory diseases. He previously spent seven years as chief operating officer (COO) at Alfact Innovation (now THAC – The Healthy Aging Company).

A biologist by training, Mariau holds a degree in life science engineering (Montpellier SupAgro and Paris Diderot University) and a master’s in management of innovation in life sciences industry (AgroParisTech and Reims Management School). He has co-authored three patents and is a member of the corporate finance committee at France Biotech. 

About Thabor Therapeutics
Thabor Therapeutics is a biotech company which specializes in the development of an innovative approach to treat patients living with chronic mucosal inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). The company’s goal is to develop first-in-class drugs that specifically target newly identified gut-secreted proteins which disrupt epithelial homeostasis.
The approach pursued by Thabor Therapeutics is based on more than ten years of research conducted by Eric Chevet, PhD, director of research at the Inserm 1242 unit in Rennes, and Eric Ogier-Denis, PhD, director of research into `Cellular Stress and Inflammatory Bowel Disease’ at Inserm, in close collaboration with Professor Xavier Treton, MD, PhD, a gastroenterologist at AP-HP (Assistance Publique – Hôpitaux de Paris university hospital center).
In 2021, the company received seed funding from AdBio partners. Based in Paris, the start-up was founded in June 2021 and currently employs six people.
www.thabor-tx.com